…
Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Arrayit Corporation (OTC: ARYC.US) is a small-cap company with limited public disclosures that appears to operate in the life‑sciences/diagnostics area based on available materials. Long-term growth drivers could include commercial adoption of diagnostic technologies, strategic partnerships or licensing, and progress on product development or regulatory milestones, though detailed information is sparse. The stock may interest investors seeking exposure to early-stage diagnostics and the potential upside from clearer disclosures or commercial traction.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Income before tax | -3.32M | -0.38M | -0.58M | -0.25M |
| Minority interest | - | - | - | -0.04M |
| Net income | -3.32M | -0.38M | 0.23M | -0.20M |
| Selling general administrative | 4.01M | 1.84M | 3.20M | 1.40M |
| Gross profit | 2.58M | 1.12M | 1.22M | 1.50M |
| Ebit | -1.49M | -0.78M | -2.05M | 0.06M |
| Operating income | -1.49M | -0.78M | -2.05M | 0.06M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M |
| Non recurring | 0.25M | 0.08M | 0.09M | - |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M |
| Total revenue | 4.38M | 2.90M | 2.49M | 3.81M |
| Total operating expenses | 5.87M | 3.68M | 4.54M | 3.75M |
| Cost of revenue | 1.80M | 1.78M | 1.27M | 2.31M |
| Total other income expense net | -1.82M | 0.40M | 1.47M | -0.31M |
| Net income from continuing ops | -3.32M | -0.38M | -0.58M | -0.25M |
| Net income applicable to common shares | -3.32M | -0.38M | 0.23M | -0.20M |
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Total assets | 1.00M | 1.54M | 0.57M | 0.50M |
| Other current assets | 0.04M | 0.19M | 0.00M | - |
| Total liab | 7.50M | 7.14M | 8.21M | 8.50M |
| Total stockholder equity | -6.50M | -5.61M | -7.64M | -7.97M |
| Other current liab | 0.48M | 0.25M | 0.49M | 0.40M |
| Common stock | 0.05M | 0.04M | 0.03M | 0.03M |
| Retained earnings | -28.01M | -24.70M | -24.32M | -24.54M |
| Other assets | 0.10M | 0.12M | 0.02M | 0.02M |
| Cash | 0.02M | 0.29M | 0.00M | 0.00M |
| Total current liabilities | 7.50M | 7.14M | 8.21M | 8.50M |
| Short term debt | 0.25M | 0.25M | 0.28M | 0.37M |
| Short long term debt | 0.25M | 0.25M | 0.28M | 0.37M |
| Other stockholder equity | -1.55M | - | - | - |
| Property plant equipment | 0.17M | 0.08M | - | 0.02M |
| Total current assets | 0.73M | 1.34M | 0.55M | 0.46M |
| Net tangible assets | -6.50M | -5.61M | -7.64M | -7.97M |
| Net receivables | 0.20M | 0.40M | 0.23M | 0.28M |
| Inventory | 0.46M | 0.46M | 0.32M | 0.18M |
| Accounts payable | 1.06M | 1.03M | 1.50M | 1.18M |
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Investments | - | - | -0.00M | - |
| Change to liabilities | 0.24M | -0.00M | 0.85M | 0.13M |
| Total cashflows from investing activities | -0.14M | -0.06M | -0.00M | -0.00M |
| Net borrowings | 0.56M | -0.15M | -0.03M | -0.21M |
| Total cash from financing activities | 0.62M | 2.21M | -0.03M | -0.21M |
| Change to operating activities | 0.23M | -0.51M | 0.00M | 0.11M |
| Net income | -3.32M | -0.38M | 0.23M | -0.20M |
| Change in cash | -0.27M | 0.29M | -0.00M | -0.01M |
| Total cash from operating activities | -0.75M | -1.86M | 0.03M | 0.20M |
| Depreciation | 0.04M | 0.04M | 0.02M | 0.03M |
| Change to inventory | -0.08M | -0.14M | -0.14M | 0.12M |
| Change to account receivables | -1.43M | -0.16M | 0.01M | -0.09M |
| Sale purchase of stock | 0.06M | 2.36M | 2.36M | 2.36M |
| Change to netincome | 3.50M | -0.68M | -0.94M | 0.10M |
| Capital expenditures | 0.14M | 0.06M | 0.06M | 0.00M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
5.51 0.80% |
692.30 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
0.17 0.07% |
228.58 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
25.06 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.38 1.56% |
23.97 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.
| Name | Title | Year Born |
|---|---|---|
| Ms. Rene A. Schena | Chairman, CEO & CFO | 1963 |
| Dr. Mark Schena Ph.D. | Pres, Chief Science Officer, Treasurer, Sec., Scientific Advisor & Director | 1963 |
| Mr. Todd J. Martinsky | Founder, Exec. VP, Scientific Advisor & Director | 1965 |
| Mr. Paul K. Haje | VP of Sales & Marketing | 1956 |
| Mr. William L. Sklar | Financial Consultant | 1948 |
| Mr. Ronald Cole | Consultant | NA |
| Dr. Mark Schena Ph.D. | President, Chief Science Officer, Treasurer, Secretary, Scientific Advisor & Director | 1963 |
| Mr. Todd J. Martinsky | Founder, Executive VP, Scientific Advisor & Director | 1965 |
| Mr. Paul K. Haje | Vice President of Sales & Marketing | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.